Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure

被引:15
|
作者
RavnikOblak, M
Mrevlje, F
机构
[1] University Medical Centre Ljubljana, Department of Endocrinolgy and Metabolism, 61000 Ljubljana
关键词
NIDDM; secondary drug failure; combined therapy;
D O I
10.1016/0168-8227(95)01137-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: Comparison of the effectiveness of combined therapy vs. an insulin regimen in NIDDM patients with secondary failure of oral hypoglycemic agents. Research design, patients and method;: 27 NIDDM patients were randomly allocated to Group A (n = 14, insulin) and Group B (n = 13, insulin and sulfonylurea) with crossover after 3 months. After the next 3 months a decision was made about the further treatment according to the metabolic control. The patients were then treated for another year with the more successful regimen. Metabolic control, residual beta-cell secretory capacity, degree of peripheral insulin resistance (clamp) and insulin dose were followed during the whole study. Results. (median, interquartile range, in brackets; *, statistically significant difference at P < 0,05): the combined therapy was better then insulin alone in 2/3 of patients. Glycemic control was better (HbA(1c) at 3 months: Group A = 7.9(1.1)% vs. Group B = 7.0(0.5)%*; HbA(1c), at 6 months: Group A = 7.4(1.5)% vs. Group B = 8.1(1.5)%. Insulin dose was lower during the combined therapy in the first 3 months: Group A = 0.62(0.18) U/kg body weight vs. Group B = 0.39(0.16) U/kg body weight*. Combined treatment was associated with increased C-peptide excretion both fasting and postprandially. No significant differences in peripheral insulin resistance were noted between the two groups. The combined treatment remained successful even after one year. The two groups of patients with different effective treatment did not differ significantly in any of the observed parameters. Conclusions: the combined therapy was more effective than insulin alone. Its favourable effect persisted after treatment for a year. It seems better to start the treatment of the oral failure with combined therapy compared with insulin first and later followed by combined therapy. On the basis of the observed parameters it is impossible to determine in advance which kind of treatment is more suitable for the individual patient.
引用
收藏
页码:27 / 35
页数:9
相关论文
共 50 条
  • [41] Secondary sulfonylurea failure: Comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide
    Satoh, J
    Takahashi, K
    Takizawa, Y
    Ishihara, H
    Hirai, M
    Katagiri, H
    Hinokio, Y
    Suzuki, S
    Tsuji, I
    Oka, Y
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2005, 70 (03) : 291 - 297
  • [42] TREATMENT STRATEGIES FOR SECONDARY SULFONYLUREA FAILURE - SHOULD WE START INSULIN OR ADD METFORMIN - IS THERE A PLACE FOR INTERMITTENT INSULIN THERAPY
    GROOP, L
    WIDEN, E
    DIABETES & METABOLISM, 1991, 17 (1BIS): : 218 - 223
  • [43] C-peptide evolution in NIDDM patients treated with lispro insulin for secondary failure to oral hypoglycemic agents.
    Gonzalo, MA
    DelPeso, C
    SanchezVilar, O
    Azriel, S
    Lara, J
    Rovira, A
    HerreraPombo, JL
    DIABETOLOGIA, 1997, 40 : 1373 - 1373
  • [44] Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents
    Kadiri, A
    Chraibi, A
    Marouan, F
    Ababou, MR
    El Guermai, N
    Wadjinny, A
    Kerfati, A
    Douiri, M
    Bensouda, JD
    Belkhadir, J
    Arvanitis, Y
    DIABETES RESEARCH AND CLINICAL PRACTICE, 1998, 41 (01) : 15 - 23
  • [45] THE COMBINATION OF INSULIN AND SULFONYLUREAS IN THE TREATMENT OF TYPE-2 DIABETES WITH SECONDARY FAILURE OF SULFONYLUREA THERAPY - LONG-TERM RESULTS
    LOTZ, N
    BACHMANN, W
    LADIK, T
    MEHNERT, H
    KLINISCHE WOCHENSCHRIFT, 1988, 66 (21): : 1079 - 1084
  • [46] DEXFENFLURAMINE - ADDITIONAL EFFECT TO INSULIN OR SULFONYLUREA IN NIDDM OBESE PATIENTS INSUFFICIENTLY CONTROLLED
    SIGNORINI, AM
    FONDELLI, C
    TANGANELLI, I
    LAVIELLE, R
    GRAGNOLI, G
    DIABETOLOGIA, 1993, 36 : A184 - A184
  • [47] Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure
    Chazan, ACS
    Gomes, MB
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2001, 34 (01) : 49 - 56
  • [48] Influence of glucagon-like peptide 1 on fasting glycaemia in NIDDM patients treated by insulin (sulfonylurea failure)
    Sauerwald, A
    Nauck, MA
    Holst, JJ
    Schmiegel, WH
    DIABETOLOGIA, 1997, 40 : 173 - 173
  • [49] The combination of insulin and metformin in treatment of non-insulin dependent diabetes mellitus (NIDDM)
    Chaudhuri, A
    Tomar, R
    Mohanty, P
    Szudzik, E
    Bandyopadhyay, A
    Arian, M
    Thusu, K
    Dandona, P
    DIABETOLOGIA, 1997, 40 : 1356 - 1356
  • [50] The combination of insulin and metformin in treatment of non-insulin dependent diabetes mellitus (NIDDM).
    Chaudhuri, A
    Tomar, R
    Mohanty, P
    Szudzik, E
    Bandyopadhyay, A
    Arien, M
    Thusu, K
    Dandona, P
    DIABETES, 1997, 46 : 1276 - 1276